Fed Regist. 2002 Dec 23;67(246):78158-72.
The Food and Drug Administration (FDA) is issuing a final rule in the form of a final monograph that establishes conditions under which over-the-counter (OTC) cold, cough, allergy, bronchodilator, and antiasthmatic (cough-cold) combination drug products are generally recognized as safe and effective and not misbranded as part of its ongoing review of OTC drug products. FDA is issuing this final rule after considering public comments on the agency's proposed regulation (tentative final monograph) and new data and information on OTC cough- cold combination drug products that have come to the agency's attention.
美国食品药品监督管理局(FDA)正在发布一项最终规则,采用最终专论的形式,规定了非处方(OTC)感冒、咳嗽、过敏、支气管扩张剂和抗哮喘(感冒咳嗽)复方药品通常被认为安全有效且不存在标签错误的条件,这是其对OTC药品持续审查的一部分。FDA在考虑了公众对该机构拟议法规(暂行最终专论)的意见以及该机构所关注的有关OTC感冒咳嗽复方药品的新数据和信息后,发布了这项最终规则。